“Emergent is committed to meeting the State Department’s need for nerve agent countermeasures that enhance the security of U.S. and allied diplomats deployed in high-risk environments worldwide,” said Sean Kirk, senior vice president, manufacturing operations and interim head, devices business unit at Emergent BioSolutions. “By leveraging our proprietary Emergard auto-injector platform and our core competencies in contracting, manufacturing, and partnering, we are confident in our ability to provide critical preparedness solutions that could address governments’ currently identified threats and emerging requirements.”

“Our priority is to provide for the safety and security of U.S. government personnel and their families deployed around the world as they carry out their mission,” said William A. Walters, M.D., managing director of operational medicine for the U.S. Department of State. “Partnering with companies such as Emergent, who can provide reliable solutions to our requirements is important in our efforts to protect against known and emerging health threats.”

The primary scope of the contract, which consists of a 12-month base period of performance with a 6-month option period, is to manufacture and deliver the Trobigard product and training auto-injectors, as well as to support the government’s emerging requirements for other existing or custom-made auto-injectors.

  • Follow us on Twitter
  • Subscribe to CBRNe news

View articles by date